20/20 Capital Management’s VanEck Pharmaceutical ETF PPH Stock Holding History

20/20 Capital Management’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$9.35M	Buy	127,911 +15,509	+14%	+$1.11M	2.42%	12
2021 Q1	$7.76M	Buy	112,402 +14,716	+15%	+$1.01M	2.25%	13
2020 Q4	$6.71M	Buy	97,686 +90,637	+1,286%	+$5.81M	1.96%	14
2020 Q3	$438K	Buy	+7,049	New	+$446K	0.16%	99

Other funds holding PPH

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

OPS

Orion Portfolio Solutions Omaha, Nebraska $10.2B AUM 6.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

20/20 Capital Management's PPH Position: Q2 2021 in Review

20/20 Capital Management increased its VanEck Pharmaceutical ETF (PPH) stake by 14% in Q2 2021, buying an estimated $1.11M and bringing the position to 127,911 shares worth $9.35M. The position accounts for 2.42% of the portfolio, ranked #12.

20/20 Capital Management first reported a position in PPH in Q3 2020 and has held it in 4 quarters since. 54 funds tracked by Wall St. Rank hold PPH as of Q2 2021.

20/20 Capital Management held 127,911 shares of VanEck Pharmaceutical ETF worth $9.35M as of Q2 2021.
20/20 Capital Management bought 15,509 VanEck Pharmaceutical ETF shares in Q2 2021, an estimated $1.11M.
VanEck Pharmaceutical ETF made up 2.42% of 20/20 Capital Management's portfolio in Q2 2021, its #12 holding.
20/20 Capital Management first reported a position in VanEck Pharmaceutical ETF in Q3 2020 and has held it in 4 quarters since.
54 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2021.

Based on 20/20 Capital Management's 13F filing for Q2 2021, filed 12 Jul 2021.